Anticipating strong quarterly earnings for Exact Sciences, TheStreet believes the Cologuard-maker is in line for growth.
Here's what you should know:
1. Exact reports its earnings Aug. 1.
2. The company's stock has jumped 23 percent since the start of the year.
3. Six analysts have awarded Exact a "buy" rating.
4. Baird's Catherine Schulte said, "We believe [Exact] is positioned to deliver on/exceed its 2018 guidance, with marketing campaigns, salesforce expansion and health system penetration all potentially helping [the second half] and beyond." She also predicted Exact will hit around $1 billion in revenues in two years.